Technology ID
TAB-3558
Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers
E-Numbers
E-068-2020-0
Lead Inventor
Hall, Matthew (NCATS)
Co-Inventors
Shen, Min (NCATS)
Kong, Ke (NCATS)
Lee, Toble
Patnaik, Samarjit (NCATS)
Lee, Olivia (NCATS)
Shrimp, Jonathan (NCATS)
Davis, Mindy (NCATS)
Marugan, Juan (NCATS)
Zhao, Wei (FDA)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Oncology
ICs
NCATS
FDA
This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express the phase 2 detoxifying enzyme SULT1A1.
Commercial Applications
Further clinical work with the YC-1 derivates could establish these heterocyclic alcohol compounds as therapies for SULT1A1 expressing cancers.
Competitive Advantages
The identification of structurally related anti-cancer compounds is a novel treatment type for SULT1A1-expressing cancer cells. In addition, the work done to establish these compounds suggests that SULT1A1 expression may serve as a biomarker for patient selection.
Licensing Contact: